Logo
x

Search

Subscribe Now

Multiple Myeloma

GSK Receives the MHRA’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma

GSK Receives the MHRA’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma

  • April 21, 2025
Johnson & Johnson Receives the EC’s Approval for Darzalex Regimen to Treat Newly Diagnosed Multiple Myeloma (NDMM)

Johnson & Johnson Receives the EC’s Approval for Darzalex Regimen to Treat Newly Diagnosed Multiple Myeloma (NDMM)

  • April 8, 2025
CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots

CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots

  • March 28, 2025
AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma

AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma

  • January 15, 2025
GSK Reports the US FDA’s BLA Acceptance of Blenrep (Belantamab Mafodotin) Regimen for Treating R/R Multiple Myeloma

GSK Reports the US FDA’s BLA Acceptance of Blenrep (Belantamab Mafodotin) Regimen for Treating R/R Multiple Myeloma

  • November 25, 2024
GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

  • November 14, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.